Overview

Under the agreement of this take-private transaction worth C$9 billion, Boralex will continue to operate as an independent private company following closing.

Our Outlook Series 2026 provides forward‑looking analysis of the most important legal, regulatory, and market developments affecting Canadian organizations.

Sanjaya Mendis is a leading intellectual property litigator and a trusted advocate for clients navigating complex patent disputes. A partner in our award-winning IP Litigation Group—recognized as Canadian Patent Litigation Firm of the Year by LMG Life Sciences for two consecutive years and consistently ranked Band 1 by Chambers—Sanjaya delivers strategic, results-driven counsel in high-stakes litigation.

With a focus on life sciences and technology, Sanjaya has built a reputation for successfully handling some of Canada’s most significant patent cases. He has deep expertise in biologic and biosimilar litigation, having acted in major mandates for Regeneron/Bayer, AbbVie, Roche/Genentech, and Moderna. His practice spans over 40 reported decisions across the Federal Court, Federal Court of Appeal, and the Supreme Court of Canada—reflecting both his litigation acumen and his commitment to achieving meaningful outcomes for clients.

Sanjaya is frequently called upon to coordinate multi-jurisdictional patent disputes, offering seamless cross-border strategy and execution. Clients value his clarity, responsiveness, and unwavering focus on their business goals. Sanjaya has acted as lead or co-lead counsel in some of Canada’s most high-profile and complex patent litigation matters. His experience spans blockbuster biologics, cutting-edge vaccines, and strategic patent advisory roles for global innovators:

Practice Areas

• Intellectual Property

Bar Information

Called to the bar: 2012 (ON)